Gedeon Richter: A Royalty with an Expiry Date, and Now a Lilly in the Garden

We have had plenty of good news on our local exchanges in recent weeks, but today we put one company in the spotlight, because it had a heck of a week: Gedeon Richter. On 10 November, Richter published strong Q1-Q3 2026 results, with Q3 net profit 6.9% above the analyst consensus, and raised its full-year guidance for the second time this year. It now expects pharma revenue to grow above 10% and Clean EBIT in the high teens, both at constant exchange rates. That alone would have made for a good week, but Richter said hold my beer. Two days later, it announced a licence deal with Eli Lilly for estetrol (E4), the hormone at the core of its women’s health business, putting currently the world’s largest pharma company on its medium to long-term horizon. The market got the message, and the share hit an all-time high of HUF 13,630, up around 38% YTD.

Under the agreement, Richter grants Lilly exclusive worldwide rights to develop, manufacture and sell medicines that combine E4, a natural and selective estrogen, with Lilly’s own compounds for women’s health conditions and cardiometabolic diseases. Lilly also gets an option to co-commercialise FYLREVY, Richter’s oral E4 menopause therapy, in the US once it is approved there. This is not a lab experiment-the European Commission approved FYLREVY in March 2026 and Richter already sells it in five countries, while the FDA accepted the US application on 14 October and expects to finish its review by Q3 2027. Under a separate supply agreement, Richter will provide Lilly with the E4 ingredient and, if Lilly takes up the US option, the finished product as well. Once the deal closes, Lilly will pay an upfront fee and buy 381,354 of Richter’s treasury shares at around USD 39.33 each, or around USD 15m for 0.2% of the company. Richter is also eligible for regulatory and commercial milestones and tiered royalties on sales. The amounts of the upfront payment, milestones and royalties were not disclosed, and the deal still needs US antitrust clearance. The full financial impact is therefore hard to pin down for now, as a new combination product will likely take Lilly several years to develop. If it works, however, we believe the sales potential could be sizable, possibly at blockbuster scale.

To see why this matters, it helps to know what Richter already has. Founded in Budapest in 1901, it is, together with Slovenia’s Krka, one of the two large Central European drugmakers still listed on their home exchange. In FY 2025 it generated pharma revenue of HUF 914.0bn (EUR 2.30bn) across four business units: Women’s Healthcare at HUF 328.6bn, Neuropsychiatry (CNS) at HUF 264.7bn, General Medicines at HUF 249.5bn and Biotechnology (biosimilars) at HUF 64.2bn.

The heart of those earnings is cariprazine, an antipsychotic developed in Richter’s own labs. Lacking a US sales force, Richter licensed the US rights to a partner, and the drug is now sold there by AbbVie as Vraylar, for schizophrenia, bipolar disorder and, as an add-on, depression. In Europe, Richter sells it itself as Reagila. AbbVie carries the selling costs, and Richter collects a royalty, which reached HUF 249.9bn in FY 2025, or 27.3% of pharma revenue. Because it costs almost nothing to earn, the CNS unit that books it delivered 75.8% of pharma Clean EBIT. The catch is the clock. US exclusivity ends on 17 March 2030, and from January 2027 Medicare will pay USD 770 per 30-day supply, 44% below the list price. The question is therefore how quickly the rest of Richter can fill the gap, and that is where E4 and Lilly come in, we believe.

Vraylar royalty and Richter’s dependence on it, 2021 to 9M 2026 (HUF bn, %)

Source: Gedeon Richter, InterCapital Research

For now, that earnings engine is still running well, although the forint makes it look less impressive. In 9M 2026, pharma revenue rose 2.6% YoY to HUF 686.5bn, but 11.7% at constant exchange rates, as the stronger forint took HUF 59.9bn out of reported revenue. Constant exchange rates show what growth would have been had currencies stayed at last year’s levels, which matters for Richter because it reports in forints but earns most of its revenue in dollars, euros and roubles. Pharma Clean EBIT rose 7.9% to HUF 229.9bn, or 25% at constant currency, a margin of 33.5%. Below the operating line, net FX losses of HUF 18.2bn also weighed, so net profit rose 7.1% to HUF 174.9bn, while free cash flow reached a record HUF 223.4bn. Beyond Vraylar, the progress is encouraging but uneven. Biotechnology made the biggest improvement, narrowing its Clean EBIT loss from HUF 13.7bn to HUF 2.0bn, with Q3 just above break-even, which accounts for HUF 11.8bn of the HUF 16.7bn YoY increase in pharma Clean EBIT (our calculation). Women’s Healthcare grew revenue 10.9% at constant currency, but its Clean EBIT fell 2.3% to HUF 37.4bn, as higher R&D, clawback and impairments absorbed the growth. General Medicines grew only 1.4% at constant currency and is behind plan.

Pharma revenue by business unit and Clean EBIT, Q1 2024 to Q3 2026 (HUF bn)

Source: Gedeon Richter, InterCapital Research

Even after the rally, Richter does not look expensive. On Bloomberg consensus for 2027, it trades at 8.8x earnings, 5.6x EV/EBITDA and 1.5x book value. Nine generic and specialty peers, from Krka and Sandoz to Teva and Viatris, trade at a median 14.4x earnings, 11.0x EV/EBITDA and 2.9x book value, while the MSCI Europe pharma index trades at 15.4x earnings. That puts Richter around 40% below its peers on P/E and at about half of them on EV/EBITDA and P/B. On top of that, Richter holds HUF 254.8bn of net cash and paid a 2025 dividend of HUF 655.45 per share, a yield of around 5%. The discount is not an oversight by the market: a single-digit multiple is how it prices a profit stream it expects to fall off sharply after March 2030.

P/E and EV/EBITDA 2027E: Richter, generic and specialty peers and European indices (x)

Source: Bloomberg, InterCapital Research

All in all, Richter is cheap for a reason, and the reason has a date on it. Three-quarters of its operating profit still comes from a royalty that loses US exclusivity in March 2030. What this week showed is that the rest of the business is growing faster than guided, and the Lilly deal is undoubtedly positive news and looks like a solid replacement. Its financial impact will take years to show, but it strengthens Richter’s medium to long-term outlook and is the first serious outside vote that E4 can become the next pillar, helping the company cope with the looming Vraylar patent cliff. From here, we will be watching the FDA’s decision on FYLREVY, the terms of the Lilly deal once it closes, AbbVie’s Vraylar outlook under the new Medicare price, whether Biotechnology stays profitable and Women’s Healthcare turns growth into earnings, and the forint.

Damian Bhaskar
Published
Category : Blog

Want to invest? Do not know how and where? Contact us and we will solve everything for you.